INAB (IN8bio) DeferredTaxAndRevenue: $0.00 Mil (As of Mar. 2026)


INAB IN8bio Inc INAB
28 GF Score
Price $1.41
View Full Analysis

What is IN8bio DeferredTaxAndRevenue?

IN8bio INAB +1.44% 28 DeferredTaxAndRevenue is $0.00 Mil as of Mar. 2026. GuruFocus rates INAB with a GF Score™ of 28/100.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

IN8bio's current deferred tax and revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

IN8bio DeferredTaxAndRevenue Related Terms

IN8bio DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for IN8bio's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IN8bio DeferredTaxAndRevenue Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

IN8bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
INAB
28GF Score
IN8bio Inc INAB
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
IN8bio (INAB) has a DeferredTaxAndRevenue of $0.00 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IN8bio.
Is IN8bio's DeferredTaxAndRevenue too high?
IN8bio's current DeferredTaxAndRevenue is $0.00 Mil. Overall, IN8bio has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does IN8bio's DeferredTaxAndRevenue compare to GDTC and LEXX?
IN8bio's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on IN8bio. IN8bio's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IN8bio stock overvalued right now?
IN8bio (INAB) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. IN8bio's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For IN8bio (INAB), the current DeferredTaxAndRevenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IN8bio Business Description

Address 350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
28GF Score

Get the complete analysis for INAB

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.41
Price